第一单位：
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
作者：
Tomas,Jelinek [1]
;
Renata,Bezdekova [2]
;
David,Zihala [1]
;
Tereza,Sevcikova [3]
;
Anjana,Anilkumar Sithara [3]
;
Lenka,Pospisilova [4]
;
Sabina,Sevcikova [5]
;
Petra,Polackova [2]
;
Martin,Stork [6]
;
Zdenka,Knechtova [6]
;
Ondrej,Venglar [7]
;
Veronika,Kapustova [1]
;
Tereza,Popkova [1]
;
Ludmila,Muronova [1]
;
Zuzana,Chyra [1]
;
Matous,Hrdinka [1]
;
Michal,Simicek [1]
;
Juan-Jose,Garcés [8]
;
Noemi,Puig [9]
;
Maria-Teresa,Cedena [10]
;
Artur,Jurczyszyn [11]
;
Jorge J,Castillo [12]
;
Miroslav,Penka [2]
;
Jakub,Radocha [13]
;
Maria Victoria,Mateos [9]
;
Jesús F,San-Miguel [8]
;
Bruno,Paiva [8]
;
Ludek,Pour [5]
;
Lucie,Rihova [2]
;
Roman,Hajek [1]
作者单位：
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
[1]
Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
[2]
Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.;Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
[3]
Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic.
[4]
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
[5]
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech Republic.
[6]
Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
[7]
Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain.
[8]
Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.
[9]
Hospital 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain.
[10]
Plasma Cell Dyscrasia Center, Department of Hematology, Jagiellonian University Medical College, Faculty of Medicine Cracow, Poland.
[11]
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
[12]
4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
[13]
DOI
10.1200/JCO.22.01226
PMID
36315921
发布时间
2023-04-04
换一批
换一批
